Navigation Links
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Date:8/19/2009

y," "likely," "designed to explore," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Femara or regarding potential future revenues from Femara. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Femara to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Femara will be submitted or approved for any additional indications or labeling in any market. Nor can there be any guarantee that Femara will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Femara could be affected by, among other things, the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements conta
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic instruments ... today that it will report financial results for the ... 2014. The Company has scheduled a conference call that ... ET to review the results. Interested ...
(Date:10/30/2014)... Oct. 30, 2014  Zimmer Holdings, Inc. (NYSE: ... future executive leadership team and organizational structure of the ... Zimmer also announced that the combined organization will leverage ... named Zimmer Biomet, with the new brand to be ... of the merger.  The future leadership team is committed ...
(Date:10/30/2014)... 2014  The number of retail health clinics in ... steadily, thanks to drug store chains, according to Kalorama ... economic downturn, retail clinic growth had been at a ... the number of retail clinics reached nearly 1,600 according ... Market Overview and 2014 Consumer Survey Results .  ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... SAN DIEGO, Dec. 9, 2011 Gen-Probe Incorporated (NASDAQ: ... Oppenheimer 22nd Annual Healthcare Conference in New York on December 14, ... to be webcast live and may be accessed through a link ... The webcast will be available for 30 days following the event. ...
... 9, 2011  Sister Carol Keehan, DC, president and chief ... United States (CHA), issued the following statement. ... Secretary Kathleen Sebelius for her intelligent and courageous decision ... unsupervised the strong hormone contained in the drug known ...
Cached Medicine Technology:Gen-Probe to Webcast Presentation at the Oppenheimer 22nd Annual Healthcare Conference 2Catholic Health Association Applauds HHS Decision on Plan B 2
(Date:10/30/2014)... new treatments for injuries and damage to the joints, ... example, is a hard material that caps the ends ... Davis biomedical engineers, exploring ways to toughen up engineered ... report new developments this week in the journal ... "The problem with engineered tissue is that the mechanical ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, plans ... that you are never too young to give back ... and Carl at the 2013 Santa Arriving By Helicopter ... Chamber of Commerce. Tracey gave Timothy a special tour ... his real fireman’s hat, and extending an offer to ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
Breaking Medicine News(10 mins):Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3
... Md., Nov. 9 Human Genome Sciences,Inc. (Nasdaq: ... JMP,Securities Sector Focus Conference will be webcast and may ... ) A member of Human Genome Sciences, ... on Tuesday, November 13, 2007 at 4:30 pm Eastern,Time. ...
... Calif., Nov. 9 Masimo (Nasdaq: MASI ),the ... Perfusion,pulse oximetry, announced today that the Pricing Committee of ... plan. "This plan is designed to enhance the ... control of the company,that do not offer an adequate ...
... SGP ) will provide a live audio webcast of ... chief financial,officer, at the 2007 Credit Suisse Health Care ... a.m. (MST) (1 p.m. EST). A live audio ... to,the Investor Relations section of the Schering-Plough corporate Web ...
... The American Stock Exchange LLC(R),(Amex(R)) announced today its final ... Health Sciences, Inc. from listing on the,Exchange, and filed ... from,listing with the Securities and Exchange Commission (the "SEC"). ... postponed by,the SEC. Pursuant to its rules, the ...
... CHICAGO (November 9, 2007) A gender difference exists ... they evaluate the factors that may influence their career ... in the November issue of the Journal of the ... a significantly higher percentage of women than men were ...
... from the University of Alabama at Birmingham (UAB) ... common anti-HIV drugs can prevent HIV-positive pregnant women ... drugs, potentially improving future treatment options., Providing tenofovir ... the extent of resistance to non-nucleoside reverse transcriptate ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:HIV drug resistance risk in mothers reduced by combination of common drugs 2
... procedures are now greatly improved with Volk's ... new lens promotes precise and focused laser ... optimized for enhanced viewing and laser treatment ... design comes standard with LaserWindow for optimal ...
... Super Macula® 2.2 offers extremely high resolution ... while achieving an exceptionally wide 78° field ... choice for critical evaluation of the optic ... detailed views of the macula and disc. ...
... Volk Area Centralis® is excellent for ... and changes from macular degeneration, retinal ... diabetic retinopathy and other retinal conditions. ... treatment of these conditions providing excellent ...
... The original 130° QuadrAspheric lens has ... 1989 as the preferred wide field fundus ... provides a definite advantage over competitive wide ... displacement, and ease of use. This lens ...
Medicine Products: